Abstracts tagged "Clinical"

Abstract Number: 791 • 2014 ACR/ARHP Annual Meeting
Comparison of Clinical Manifestations in Different Histological Subsets of Biopsy-Proven Giant Cell Arteritis
Luigi Boiardi¹, Francesco Muratore¹, Alberto Cavazza², Giovanna Restuccia³, Pierluigi Macchioni¹, Giuseppe Germanò¹, Nicolò Pipitone¹, Gianluigi Bajocchi⁴ and Carlo Salvarani¹, ¹Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ²Pathology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ³Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ⁴Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Japan
Background/Purpose: Temporal artery biopsy (TAB) showing transmural inflammation is considered the gold standard for the diagnosis of giant cell arteritis (GCA). In some cases of…
Abstract Number: 790 • 2014 ACR/ARHP Annual Meeting
Correlations Between Histopathological Findings and Clinical Manifestations in a Large Monocentric Cohort of Patients with Biopsy-Proven Giant Cell Arteritis
Luigi Boiardi¹, Francesco Muratore¹, Giovanna Restuccia², Alberto Cavazza³, Pierluigi Macchioni¹, Giuseppe Germanò¹, Nicolò Pipitone¹ and Carlo Salvarani¹, ¹Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ²Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ³Pathology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy
Background/Purpose: Giant cell arteritis (GCA) is a vasculitis that involves large and medium sized arteries in patients older than 50 years. Temporal artery biopsy (TAB)…
Abstract Number: 789 • 2014 ACR/ARHP Annual Meeting
Association Between Histological Features and Clinical Features of Patients with Biopsy Positive Giant Cell Arteritis
Kimberley Ting¹, Susan Lester² and Catherine L. Hill³, ¹Rheumatology, The Queen Elizabeth Hospital, Adelaide, Australia, ²Rheumatology Unit, Queen Elizabeth Hospital, Woodville South, Australia, ³Discipline of Medicine, University of Adelaide, Adelaide, Australia
Background/Purpose: Temporal artery biopsy is the gold standard for diagnosing giant cell arteritis (GCA). The pathology of GCA characteristically involves transmural infiltrates, giant cell formation…
Abstract Number: 722 • 2014 ACR/ARHP Annual Meeting
Prediction of Improvement in Skin Fibrosis in Diffuse Cutaneous Systemic Sclerosis
Rucsandra Dobrota^1,2, Britta Maurer¹, Nicole Graf³, Carina Mihai², Otylia Kowal-Bielecka⁴, Yannick Allanore⁵ and Oliver Distler on behalf of the EUSTAR investigators and co-authors¹, ¹Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Department of Internal Medicine and Rheumatology, Dr.I.Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ³graf biostatistics, Winterthur, Switzerland, ⁴Department of Rheumatology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland, ⁵Department of Rheumatology, University Paris Descartes and Cochin Hospital, Paris, France
Background/Purpose Improvement of skin fibrosis over time is part of the “natural history” of patients with diffuse cutaneous systemic sclerosis (dcSSc). However, in the individual…
Abstract Number: 2309 • 2013 ACR/ARHP Annual Meeting
Quantifying The Gap Between General Population Guidelines and Expert Opinion For Cardiovascular Risk Management In Rheumatic Disease Patients
Katherine P. Liao¹, Jonathan Brown², Jonathan S. Coblyn³, Paul Cohen², Jorge Plutzky² and Daniel H. Solomon⁴, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Cardiology, Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA
Background/Purpose: Cardiovascular (CV) risk is higher among rheumatic disease patients than the general population. However, CV risk management guidelines calibrated for the rheumatic disease population…
Abstract Number: 2131 • 2013 ACR/ARHP Annual Meeting
Osteoarthritis Pain: Variability and Clinical Correlations
Thomas J. Schnitzer¹, Renita Yeasted², Leijan Huang³, Jennifer Duffecy⁴, Mark Begale⁴ and A. Vania Apkarian³, ¹PM&R and Int Med, Northwestern University, Chicago, IL, ²PM&R, Northwestern University, Chicago, IL, ³Physiology, Northwestern University, Chicago, IL, ⁴Preventive Medicine, Northwestern University, Chicago, IL
Background/Purpose: Although osteoarthritis (OA) is an intensely studied model of chronic pain, little is known about the temporal dynamics of OA pain intensity and how…
Abstract Number: 2062 • 2013 ACR/ARHP Annual Meeting
Clinical Features and Outcome In Polymyositis Vs. Dermatomyositis Patients With The Anti-Jo-1 Autoantibody
Rohit Aggarwal¹, Diane Koontz², Zengbiao Qi³ and Chester V. Oddis⁴, ¹Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Department of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The clinical characteristics of dermatomyositis (DM) patients possessing the anti-Jo-1 autoantibody (autoAb) are not well known. We analyzed the clinical features and prognosis of…
Abstract Number: 1796 • 2013 ACR/ARHP Annual Meeting
12-Week Results Of a Phase 2b Dose-Ranging Study Of Baricitinib, An Oral JAK1/ JAK2 Inhibitor In Japanese Patients With Rheumatoid Arthritis On Background Methotrexate Therapy
Yoshiya Tanaka¹, Kahaku Emoto², Mika Tsujimoto², Douglas E. Schlichting³ and William Macias³, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Eli Lilly Japan K.K., Kobe, Japan, ³Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib (formerly LY3009104/INCB028050), a novel, oral inhibitor of JAK1 and JAK2 in the JAK-STAT signaling pathway, has been evaluated in a 12-week blinded phase…
Abstract Number: 1336 • 2013 ACR/ARHP Annual Meeting
The Safety and Feasibility Of a Treat-To-Target Strategy Aimed At Achieving a Simplified Disease Activity Index Of ¡Ü3.3 While Administering Entecavir In Rheumatoid Arthritis Complicated By Hepatitis B Virus
Yukitomo Urata¹, Yoshihide Nakamura^2,3 and Ken-ichi Furukawa⁴, ¹Seihoku Central Hospital, United Municipalities of Tsugaru, Gosyogawara, Japan, ²Hirosaki University Graduate School of Medicine, Hirosaki, Japan, ³Orthopaedic Surgery, Seihoku Central Hospital, United Municipalities of Tsugaru, Gosyogawara, Japan, ⁴Pharmacology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
Background/Purpose: To elucidate the safety and feasibility of a treat-to-target (T2T) strategy aimed at achieving a simplified disease activity index (SDAI) of ≤3.3 while administering…
Abstract Number: 1305 • 2013 ACR/ARHP Annual Meeting
Clinical Joint Involvement Is Decisive For Radiographic Progression
Miriam Gärtner¹, Farideh Alasti², Gabriela Supp¹, Josef S. Smolen³ and Daniel Aletaha¹, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: Today’s therapeutic targets in rheumatoid arthritis (RA) are remission or low disease activity, but it was shown that joint damage may continue to progress…
Abstract Number: 33 • 2013 ACR/ARHP Annual Meeting
B Cell Receptor Signaling As A Potential Clinical Parameter In Lupus
Michael Faludi¹, Christian A. Pineau², Evelyne Vinet¹, Ann E. Clarke³, Sasha Bernatsky⁴, Joyce Rauch² and Emil P. Nashi⁵, ¹McGill University Health Center, Montreal, QC, Canada, ²Rheumatology, McGill University Health Center, Montreal, QC, Canada, ³Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, ⁴Division of Clinical Epidemiology, McGill University Health Center, Montreal, QC, Canada, ⁵Immunology and Rheumatology, McGill University Health Center, Montreal, QC, Canada
Background/Purpose: B cells are central to SLE. Signaling through the B cell receptor (BCR) controls critical processes at various stages of B cell development. Murine…
Abstract Number: 125 • 2013 ACR/ARHP Annual Meeting
Correlation Of Findings In Clinical and High Resolution Ultrasonography Examinations Of The Painful Shoulder
Raphael Micheroli¹, Diego Kyburz², Adrian Ciurea³, Beat Dubs⁴, Martin Toniolo², Samuel Bisig⁵ and Giorgio Tamborrini⁶, ¹Faculty of Medicine, University of Zurich, Zurich, Switzerland, ²Department of Rheumatology, University Hospital of Zurich, Zurich, Switzerland, ³Center of Experimental Rheumatology, University Hospital Zurich, Zurich Schlieren, Switzerland, ⁴Sonography Institute Bethanien Zurich, Zurich, Switzerland, ⁵Swiss Federal Institute of Technology Zurich, Zurich, Switzerland, ⁶Department of Rheumatology and Musculoskeletal Ultrasound, Bethesda Hospital Basel, Basel, Switzerland
Background/Purpose: High resolution ultrasonography (HRUS) is a non-painful and non-invasive imaging technique which is increasingly used for evaluating patients with musculoskeletal disorders. In particular, HRUS…
Abstract Number: 2527 • 2013 ACR/ARHP Annual Meeting
Association Of Nail Dystrophy With Capillaroscopic Abnormalities, Anti-Endothelial Cell Antibody, Endothelin-1, Activity and Chronicity In Systemic Lupus Erythematosus
Violeta Higuera¹, Luis M. Amezcua-Guerra², Felipe Massó³, Mariana Patlan⁴, Hugo Montoya⁵, Araceli Paez⁴ and Luis H. Silveira⁶, ¹Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, Mexico, ²Rheumatology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, ³Immunology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, ⁴Immunology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, Mexico, ⁵Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, Mexico, ⁶Rheumatology, Instituto Nacional Cardiología Ignacio Chávez, Mexico City, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of unknown etiology, characterized by a broad spectrum of clinical manifestations. There is a large…
Abstract Number: 2387 • 2012 ACR/ARHP Annual Meeting
Takayasu’s Arteritis: Features and Management of 216 Patients in China
Xia Liu¹, Tao Zhang², Xiaofeng Zhuang³, Kai Yuan¹, Xiaoming Shu¹ and Guochun Wang¹, ¹Department of Rheumatology and Immunology, China-Japan Friendship Hospital, Beijing, China, ²Department of Vascular Surgery, Chinese PLA General Hospital, Beijing, China, ³Department of Cardiology, FuWai Hospital and Cardiovascular Institute, Beijing, China
Background/Purpose: Takayasu’s arteritis (TA) is a rare vasculitis. Although it appears to be most common in Asia countries, research on Chinese TA patients with large…
Abstract Number: 2233 • 2012 ACR/ARHP Annual Meeting
Assessing the Clinical and Economic Burden of U.S. Veteran Ankylosing Spondylitis Patients
Lin Xie¹, Onur Baser², Ahong Huang³, Lu Li³, Elyse K. Fritschel³ and Li Wang⁴, ¹Director, Health Economics & Outcomes Research, STATinMED Research, Ann Arbor, MI, ²President/Adjunct Professor of Internal Medicine, STATinMED Research/The University of Michigan, Ann Arbor, MI, ³STATinMED Research, Dallas, TX, ⁴Director, Analytic Research, STATinMED Research, Dallas, TX
Background/Purpose: To examine the economic burden, demographic and clinical characteristics of ankylosing spondylitis (AS) in the U.S. veteran population. Methods: A retrospective database analysis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].